A landmark paper on homeopathy and cancer appeared in the February 2010 issue of
the International Journal of Oncology. Scientists at the University of Texas M.D.
Anderson Cancer Center (MDA), led by Dr. Moshe Frenkel, have demonstrated the beneficial
effects of homeopathic medicines on breast cancer cells. Four ultra-dilute remedies
were used in the study i.e. Carcinosin, Phytolacca, Conium and Thuja.
According to the researchers: "The remedies exerted preferential cytotoxic effects
against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis".
It was particularly interesting that the cell-killing effects of two of the remedies
investigated in the study i.e. Carcinosin and Phytolacca, appeared similar to the
activity of paclitaxel (Taxol), the most commonly used chemotherapeutic drug for
breast cancer, without the toxic effect on the normal cells. The findings demonstrated
biological activity of these products when presented at ultra-diluted doses.
According to Dr. Frenkel: "This is the first scientific study that investigated the
effect of homeopathic remedies on breast cancer cells." Dr. Frenkel referred to its
significance as an "exciting possibility" because of the "therapeutic opportunity
for preferentially eliminating breast cancer cells with minimal damage to the surrounding
normal mammary tissue by using homeopathic remedies."
Background to the study:
In 1999 the US National Cancer Institute (NCI) in the United States evaluated a cancer
treatment protocol developed at the P. Banerji Homeopathic Research Foundation (PBHRF)
in Kolkata, India. The ‘Banerji protocol’ used specific ultra-diluted natural substances
to treat patients with different cancers. The NCI reviewed 10 patients treated on
the Banerji protocol. In four of the cases with lung and esophageal cancers, the
NCI confirmed partial responses. All patients reviewed had appropriate pathology
and imaging studies to confirm diagnosis and response. The patients only received
the remedies prescribed at the PBHRF clinic and did not receive any additional conventional
treatment, such as surgery, radiation, or chemotherapy. After rigorous evaluation,
the NCI concluded that there was sufficient evidence of efficacy to warrant further
research of the Banerji protocol. As a result of growing interest in Banerji protocol
remedies among patients at the M.D. Anderson Cancer Center of the University of Texas,
most of whom have advanced breast cancer, a team of researchers decided to evaluate
the in-vitro effect of those remedies and the landmark paper in the International
Journal of Oncology was the result.